Every Woman Deserves the Best Option for Breast Cancer Treatment

October is Breast Cancer Awareness Month, a time of year when people around the world, including the Accuray team, join together to honor the millions of breast cancer patients and survivors. Our legacy of patient-first innovation drives unique capabilities for the confident treatment of breast cancer.

A promising option for partial breast irradiation after breast-conserving surgery.

The true robotic precision and motion synchronization & real-time adaptive capabilities of the CyberKnife® System provides choices for early stage breast cancer patients treated post-lumpectomy.

Two recent clinical studies indicate stereotactic accelerated partial breast irradiation (APBI) delivered with the CyberKnife System and Synchrony technology enabled precise treatments while limiting toxicity and preserving cosmesis.

An effective clinical solution for routine and complex breast cancer treatments.

The Radixact® System, the next-generation TomoTherapy® platform, provides a personalized, precise and non-invasive option for treating breast cancer, typically a post-lumpectomy or mastectomy. The system is the world’s first helical radiotherapy platform, delivering highly accurate radiation dose from 360 degrees around the patient. Multiple clinical studies show that the TomoTherapy System can provide excellent outcomes for breast cancer patients.

Clinical Studies Offer Hope for Breast Cancer Patients

ESTRO Abstracts


  • PD-0779: Fiducial motion relative to tumor bed in partial breast irradiation and risk of geographical miss. N. Hoekstra1, S. Habraken1, A. Swaak – Kragten1, J. Pignol2, M. Hoogeman1. 1Erasmus MC Cancer Institute, Radiotherapy, Rotterdam, The Netherlands; 2Dalhousie University,
    Radiotherapy, Halifax, Canada
  • PO-1138: Preoperative radiation therapy in breast cancer: preliminary results from ROCK trial (NCT03520894). V. Di Cataldo1, G. Francolini2, L. Visani1, C. Becherini2, E. Scoccimarro3, L. Masi1, R. Doro1, G. Salvatore4, S.Bianchi5, V. Vezzosi6, E. Lemmi6, J. Nori7, L. Sanchez8, L. Orzalesi8, M. Bernini8, M. Loi2, I. Desideri4, M.Mangoni4, I. Meattini4, L. Livi4. 1IFCA, Cyberknife, Florence, Italy; 2Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Oncology Department, Florence, Italy; 3University of Florence, Department of Experimental and Clinical Biomedical Sciences Mario Serio, Florence, Italy; 4University of Florence, Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, Florence, Italy; 5 Azienda Ospedaliero-Universitaria Careggi, Division of Pathological Anatomy, Florence, Italy; 6Azienda Ospedaliero-Universitaria Careggi, Division of Pathological Anatomy, Florence, Italy; 7Azienda Ospedaliero-Universitaria Careggi, Diagnostic Senology Unit, Florence, Italy; 8Azienda Ospedaliero-Universitaria Careggi, Breast Surgery Unit, Florence, Italy

TomoTherapy Treatment



CyberKnife Treatment



Table of Contents